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Abstract
Background: Valid detection of inflamed joints is essential for correct classification, therapeutic decisions, prognosis
and assessment of treatment efficacy in juvenile idiopathic arthritis (JIA). Fluorescence optical imaging (FOI) enables
visualization of inflammation in arthritis of finger and hand joints and might be used for monitoring.
Methods: A 24-week observational study in polyarticular JIA patients newly starting treatment with methotrexate or
an approved biologic was performed in three centers. Patients were evaluated clinically, by gray-scale ultrasonography
(GSUS), power-Doppler ultrasonography (PDUS) and FOI at baseline, week 12 and week 24.
Results: Of 37 patients enrolled, 24 patients started methotrexate and 13 patients a biologic for the first time (etanercept
n= 11, adalimumab and tocilizumab n= 1 each). Mean JADAS 10 decreased significantly from 17.7 at baseline to 12.2 and
7.2 at week 12 and 24 respectively. PedACR 30/50/70/100 response rates at week 24 were 85%/73%/50%/27%. The total
number of clinically active joints in hand and fingers at baseline/week 12/week 24 was 262 (23.6%)/162 (16.4%)/162
(9.0%). By GSUS, at baseline/week 12/week 24, 192 (19.4%)/135 (16.1%)/83 (11.5%) joints showed effusions and
186 (18.8%)/107 (12.7%)/69 (9.6%) showed synovial thickening, and by PDUS 68 (6.9%)/15 (1.8%)/36 (5%) joints
showed hyperperfusion. Any sign of arthritis was detected by US in a total of 243 joints (24.5%) at baseline,
161 joints (19.2%) at week 12 and 123 joints (17%) at week 24. By FOI at baseline/week 12/week 24, 430 (38.7%)/
280 (29.2%)/215 (27.6%) showed a signal enhancement in at least one phase.
Summarizing all three points of time, the highest numbers of signals were detected by FOI with 32% of joints,
especially in phase 2, while by US 20.7% and by clinical examination 17.5% of joints were active. A high number of
joints (21.1%) had FOI signals but were inactive by clinical examination. A total 20.1% of joints with signals in FOI did
not show effusion, synovial thickening or hyperperfusion by US.
Because of the high number of negative results, specificity of FOI compared with clinical examination/US/PD was high
(84–95%), and sensitivity was only moderate.
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Conclusion: FOI and US could detect clinical but also subclinical inflammation. FOI detected subclinical inflammation
to a higher extent than US. Improvement upon treatment with either methotrexate or a biologic can be visualized by
FOI and US.
Trial registration: Deutsches Register Klinischer Studien DRKS00011579. Registered 10 January 2017.
Keywords: Juvenile idiopathic arthritis, Imaging, Fluorescence optical imaging, Xiralite, Arthrosonography,
Ultrasonography, Power Doppler
Background
Juvenile idiopathic arthritis (JIA) is the most common
chronic inflammatory rheumatic disease in childhood
and can lead to severe disability [1–3]. The validity of
diagnosis, classification and prognosis as well as thera-
peutic decisions for each JIA patient depends on reliable
detection of joint involvement. Careful clinical assess-
ment is of great importance but may be difficult, espe-
cially in children. Subclinical inflammation could also be
missed, for example in early stages of the disease or with
minimal disease activity. Ultrasonography (US) in gray-
scale (GSUS) and power Doppler (PDUS) modes is often
available for assessment of synovial thickening, joint
effusions and hyperperfusion, thus helping to detect ac-
tive joints. In clinical practice this procedure is usually
used on a limited number of joints due to limitations of
time. Fluorescence optical imaging (FOI) is a contrast-
enhanced optical procedure for visualization of
changes in microcirculation. It has been used for over
30 years for various indications [4]. In experimental
models of arthritis, indocyanine green (ICG)-enhanced
FOI findings corresponded to histologically proven
synovitis [5, 6]. This approach was also tested in
humans [7, 8]. FOI is time efficient and operator in-
dependent. The image interpretation, however, is
dependent on visual perceptions and imaging experi-
ence of the examiner and is limited to wrist and fin-
ger joints. Increased focal optical signal intensities
visualize areas of high perfusion, altered microcircula-
tion and/or capillary leakage, which may not show in
GSUS, especially in the small finger joints [9–11]. In
adult RA patients, FOI has been shown to be a reli-
able technique to detect inflammation with good
agreement with magnetic resonance imaging (MRI).
The authors distinguished three different phases and
a computer-generated composite image; their meaning
still being unclear, they may give varying information
such as changes in perfusion, microcirculation, capil-
lary leakage or neovascularization. In the opinion of
the authors, very early arthritis could be observed
with FOI as well as subclinical inflammation [10, 11].
FOI might be a valuable tool to assess subclinical and
very early arthritis, to differentiate between arthritis and
pain syndrome and to assess treatment response.
This observational study intended to analyze improve-
ment upon newly instituted treatment with a DMARD
or with a biologic clinically, using commonly used tools
(PedACR, JADAS, number of active, swollen and tender
joints) and by imaging methods (GSUS and PDUS) as
well as by FOI. We intended for the first time to com-
pare clinical and imaging results with the new FOI
method to explore the clinical utility. Of further interest
is the presentation of residual inflammation which might
not be detected clinically but by imaging and whether an
early decrease of inflammation detected by FOI is pre-
dictive for remission later on.
The results of the first study using the FOI technique
and US examination in children with JIA before and
during antirheumatic treatment are reported here.
Methods
Patients
In three German centers a total number of 37 patients
starting a new treatment with either a DMARD or a bio-
logic approved for polyarticular JIA were recruited for
this observational study. Inclusion criteria were: diagno-
sis of polyarticular JIA according to ILAR criteria (sero-
positive, seronegative polyarthritis JIA and extended
oligoarthritis) [12], active disease with at least three clin-
ically active joints in the hand region, age 6–18 years
and agreement of patient and parents/legal guardian to
participate in the study. Patients had to be either naïve
to methotrexate in the cohort starting methotrexate or
naïve to any biologic.
The study was performed in compliance with the Dec-
laration of Helsinki. The study protocol was approved by
the ethics committee Ärztekammer Nordrhein (Number:
2012026) and the ethics committee of the Charité uni-
versity clinic Berlin (Number EA2/039/12). Written in-
formed consent forms were obtained for all participants.
Clinical and laboratory assessment
All patients were evaluated by clinical examination (CE)
at baseline, after 12 and 24 weeks. Swollen, tender joints
and joints with limitation of motion (LOM) were scored
for presence or absence (0–1). Joints with swelling not
due to deformity or joints without swelling, LOM plus
pain and/or tenderness were defined as active joints.
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The ESR and C-reactive protein (CRP) test were re-
corded at each visit. Disease activity was also measured
by patient/parent visual analog scale (0–100) of overall
well-being, by physician visual analog scale of overall
disease activity and by CHAQ scores (0–3) [13]. The
JADAS 10 score was calculated for each visit [14].
Ultrasonography
Thirty joints were examined by ultrasonography for each
patient (wrists, MCP 1–5, PIP 1–5, DIP 2–5) at three
different time points (week 0, 12 and 24). Evaluation was
done semiquantitatively (grades 0–3) for synovial thick-
ening, joint effusions in GSUS and hyperperfusion in
PDUS according to Manggi-Manzoni et al. [15]. Joints
graded 1–3 were scored as active in the respective exam-
ination mode [10]. Ultrasonography examination was
performed using LOGIQ e notebook with 12-MHz linear
transducer by General Electrics Healthcare, Toshiba
Aplio XG and MyLab70 XVG Esaote.
Fluorescence optical imaging
At each visit (week 0, 12 and 24) a standardized FOI
examination was performed as described by Werner et
al. [10, 11]. An ICG bolus (ICG-Pulsion®, 0.1 mg/kg BW;
Pulsion Medical Systems AG, Munich, Germany) was
injected into the cubital vein; thereafter one image/sec-
ond over 6 minutes was obtained, resulting in 360 im-
ages. Three phases according to signal intensities in the
fingertips and an electronically generated composite
image (CI), automatically obtained by means of the inte-
grated software XiraView (version 3.6), were analyzed.
Phase 1 includes all images until clearly increased signal
intensities are visible in the fingertips, phase 2 includes
all images during increased intensities in the fingertips
and phase 3 includes all images from the end of phase 2
until the end of the examination. For each phase and the
composite image, each joint was scored semiquantita-
tively (0–3: 0 = no increased signal intensity; 1 = low in-
creased signal intensity, <25% of affected joint area; 2 =
moderate intensity, >25 and <50% of affected joint area;
and 3 = strong increased signal intensity, >50% of af-
fected joint area). Joints were counted as active if they
reached at least a score of 1 [10, 11]. The commercially
available Xiralite X4 device (Mivenion) was used for the
examination. Reading was done by a single experienced
observer, who had knowledge of the typical pitfalls of
FOI interpretation.
Efficacy parameters
Clinical response was measured by the pediatric ACR
(PedACR) criteria, JADAS reduction and reduction in
the number of active joints. PedACR improvement was
calculated as described previously in detail [16]. The cat-
egories contributing to the PedACR 30 Score are
physician’s global assessment of the subject’s disease ac-
tivity (numeric rating scale (NRS)), parents’ global as-
sessment of the subject’s overall well-being (NRS),
number of active joints (swelling not due to deformity or
in joints without swelling, LOM plus pain and/or ten-
derness), number of joints with LOM, Childhood Health
Assessment Questionnaire (CHAQ) and CRP. The
JADAS minimal disease activity (defined as JADAS10 ≤
3.8) and the JADAS remission activity (defined
JADAS10 ≤ 1) according to the definition of Consolaro
et al. [17] was calculated.
Safety parameters
Clinical and laboratory evidence of adverse events was
investigated at each study visit. The investigator assessed
and recorded any adverse event in detail on the adverse
event form, including the date and time of onset, de-
scription, severity, time course, duration and outcome,
relationship of the adverse event to the study drug and
alternative etiology for events not considered ‘probably
related’ to the study drug.
Statistical analysis
Analyses were conducted at patient and individual joint
levels. Mean values and standard deviations were calcu-
lated for quantitative variables. Demographic and base-
line characteristics were summarized by descriptive
statistics. Efficacy and safety analyses were performed in
the intention-to-treat population (ITT), and tests were
two-sided. p < 0.05 was considered statistically signifi-
cant. Frequencies were compared using the chi-square
test or Fisher’s exact test as appropriate. Agreement was
reached when a joint was assessed as affected (>0) or
not affected (0) with both modalities. Clinical examin-
ation and ultrasonography was used as the standard
reference method for calculation of sensitivity and speci-
ficity. Receiver operating characteristic (ROC) curves
were generated to assess sensitivity and specificity of
FOI versus ultrasonography and clinical standards of
care. The area under the curve (AUC) was calculated.
Improvement of continuous disease activity parameters
were compared using the t test. Data were entered into
an Access 2010 database and analyzed with Excel 2010




Thirty-seven patients with active polyarticular JIA were
enrolled in this study. Of these, 24 patients started treat-
ment with methotrexate and 13 patients received ther-
apy with a biologic for the first time (11 patients started
etanercept, one patient adalimumab and one patient
tocilizumab). Thirty-four patients (21 on methotrexate
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and 13 on biologic) could be evaluated at week 12, and
25 patients (17 on methotrexate, eight on biologic) com-
pleted the study through week 24. Mean age at enroll-
ment was 13.9 years (range 9–18 years).
There were no significant differences regarding pa-
tient characteristics and disease activity parameters be-
tween the two cohorts at baseline, although patients in
the biologics cohort tended to have higher disease
activity parameters than patients in the methotrexate
cohort (Table 1).
Of all patients, 35% received oral corticosteroids at
baseline. Also the number of patients using oral cortico-
steroids at baseline was slightly but insignificantly higher
in the biologics cohort (seven of 13 patients) than in the
methotrexate cohort (six of 24 patients). No patient had
active uveitis or history of uveitis and no patient had
signs or history of systemic inflammation.
Efficacy
Response rates according to the PedACR 30/50/70/100
and the JADAS in this study were as expected. After
12 weeks of treatment, PedACR 30/50/70/100 scores
were reached by 69%/45%/24%/10% in the methotrexate
cohort and 82%/45%/19%/0% in the biologics cohort.
Response rates improved further until week 24, with
85%/73%/50%/27% reaching PedACR 30/50/70/100
scores (83%/72%/44%/22% in the methotrexate cohort
and 88%/75%/63%/38% in the biologics cohort).
All but eight patients showed decreased JADAS 10
scores at week 12, and four of these showed JADAS
improvement at week 24. Mean JADAS 10 values de-
creased significantly during treatment for all pa-
tients. In the cohort completing week 24 of this
study, the mean JADAS 10 values decreased from
17.7 at baseline to 12.2 at week 12 and 7.2 at week
24. Patients treated with DMARDs showed a de-
crease from 18.8 at baseline to 12.7 at week 12 and
7.6 at week 24. Patients treated with biologics
started with a higher JADAS of 19.6 at baseline, but
then decreased more rapidly to a JADAS 10 of 11 at
week 12 and further to 6.1 at week 24.
Clinical examination
In total, 2970 separate joints of the hand region were
evaluated by CE at three different points of time; of
these, 2551 joints had complete data for US evaluation
and 2910 had complete datasets for FOI analysis.
Altogether, 519 of 2970 joints (17.5%) were clinically
classified as active (434 (14.6%) swollen joints, 542
(18.2%) tender joints and 348 (11.7%) joints with limited
range of motion). The joints PIP 2 and 3, followed by
PIP 4 and 5, MCP 2 and 3 and the wrist were affected
most frequently.
At baseline, 1110 joints were evaluated by CE and with
FOI, and 990 joints were evaluated with US. In CE, 262
of the 1110 joints (23.6%) were classified as active joints
(237 (21.4%) swollen joints, 267 (24.1%) tender joints
and 181 (16.3%) joints with limited range of motion).
Upon treatment with either methotrexate or a bio-
logic, a significant decrease of the mean number of ac-
tive/swollen/tender or LOM joints at week 12 and week
24 compared with baseline was documented (Fig. 1a).
At week 12, 162 of 990 joints (16.4%) of the hand re-
gion evaluated by CE were assessed as clinically active.
This decreased further in week 24 to 70 of 780 (9.0%).
Table 1 Patients’ baseline characteristics
All patients (n = 37) DMARD cohort (n = 24) Biologics cohort (n = 13)
Male/female 7/30 5/19 2/11
Age (years) 13.9 (2.2) 14.3 (2.1) 13.5 (2.4)
Disease duration (years) 3.6 (3.2) 3.2 (4.1) 4.1 (3.7)
CHAQ-DI 0.61 (0.7) 0.54 (0.58) 0.66 (0.84)
JADAS 10 16.9 (5.7) 15.5 (5.6) 19.0 (5.0)
ESR (mm/h) 17.6 (20.1) 18.9 (21.8) 14.4 (15)
CRP(mg/l) 5.0 (12.2) 2.7 (4.5) 8.7 (18.3)
Physician Global Assessment VAS (cm) 4.8 (2.1) 4.4 (1.8) 5.5 (2.3)
Parents Global Assessment VAS (cm) 4.5 (2.5) 4.5 (2.1) 4.5 (3.2)
Number of active joints 7.1 (5.2) 6.7 (5.2) 8.3 (5.0)
Number of tender joints 9.6 (8.9) 9.6 (8.0) 10.0 (11.4)
Number of swollen joints 7.2 (5.7) 6.8 (5.7) 8.1 (5.5)
Number of joints with LOM 6.5 (6.7) 5.4 (5.3) 8.4 (8.4)
Data presented as number or mean (standard deviation)
DMARD disease-modifying antirheumatic drug, CHAQ Childhood Health Assessment Questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate,
JADAS Juvenile Diseases Activity Score, LOM limitation of motion, VAS visual analog scale
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Ultrasonography findings
At baseline, 990 joints of the hand region were evaluated
by US examination. Here 192 joints (19.4%) showed joint
effusions, 186 joints (18.8%) showed signs of synovial
thickening on GSUS and 68 joints (6.9%) showed signs
of hyperperfusion on PDUS. These numbers had de-
creased at week 12 to 135 joints (16.1%) with joint effu-
sions, 107 joints (12.7%) with synovial thickening and 15
joints (1.8%) with hyperperfusion of 840 joints of the
hand region evaluated by US. At week 24, 720 joints of
the hand region were assessed by US. While the num-
bers of joints with joint effusions and synovial thickening
improved further (83 and 69 joints (11.5% and 9.6%) re-
spectively), more joints showed signs of hyperperfusion
compared with week 12 (36 joints (5%)).
At baseline, in total 243 joints (24.5%) showed signs of
inflammation for any of the three US parameters, 161
joints (19.2%) at week 12 and 123 joints (17%) at week
24. As outlined in Fig. 1b, a decrease of the mean num-
ber of joints with effusion, synovial thickening and hy-
perperfusion at week 12 and week 24 compared with
baseline was documented.
Fluorescence optical findings
Overall, FOI revealed focal joint-related increased signal
intensity as signs of synovitis/tenosynovitis in 947 joints.
At baseline, 430 of 1110 evaluated joints (38.7%) showed
increased signal intensity in one or more phases in FOI.
This figure decreased to 280 of 960 evaluated joints
(29.2%) at week 12 and 215 of 780 evaluated joints
(27.6%) at week 24. With the phase1/phase 2/phase 3
and composite image, 215/369/108 and 266 joints were
detected at baseline, 93/229/45 and 142 joints at week
12 and 84/166/26 and 115 joints at week 24 (Fig. 1c).
Mean semiquantitative intensity of FOI signals in all ex-
amined joints decreased significantly between baseline
and week 12 in all three phases and the composite image
(p < 0.0001 for all), with only minimal changes between
weeks 12 and 24.
Figure 2a shows FOI examinations of one patient at
the three different time points. At baseline, high signals
in FOI were noted, especially in PIP joints and in phase
2. These joints were also assessed active by clinical
examination. All but one of the joints showed signs of
effusions and most also synovial thickening on US, and
PIP 3 of the right hand also showed hyperperfusion by
PD. Upon treatment, the number of joints as well as the
signal intensity decreased. At week 24, residual inflam-
mation was visible by FOI and by clinical investigation
especially in PIP 2–5 of the left hand.
Figure 2b shows FOI examinations of a second patient
at four different time points. At baseline, both wrists and
PIP 2–5 joints of both sides showed high signals in FOI,
especially in phase 2 and in the composite image. In
addition, signals over the DIP region indicate DIP joint in-
volvement but cannot be clearly distinguished from finger-
tip hyperemia. Clinically DIP 2–5 of the left hand, MCP 1
of the left hand and PIP 2–5 of both hands were assessed
as active, only PIP 2, 4 and 5 of the left hand showed
sonographic effusions and PIP 5 of the left hand showed
synovial thickening. Upon treatment, the number of joints
as well as the signal intensity decreased. At week 24,
a b
c
Fig. 1 Mean affected joints of the hand region for the three examination techniques before the start of treatment and after 12 and 24 weeks of
treatment. a Clinical examination. b US/PD examination. c Signal intensity on FOI examination. Mean values and standard deviations are shown.
LOM limitation of motion, CI composite image, Ph phase
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B1 B2 B3 B4
C1 C2 C3 C4
D1 D2 D3 D4
b
Fig. 2 (See legend on next page.)
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residual inflammation was visible in the region of PIP
joints and wrist, while clinically and with US/PD no joint
was assessed as active. Thus, clinically the patient was in
remission, showing residual inflammation in FOI only.
This patient had an FOI examination 1 year after baseline
following completion of the study, while reporting pain in
DIP and wrist joints. Clinically there were no abnormal
findings in joint status and US/PD. FOI showed only
minor signal enhancement.
Predictive value of FOI and clinical outcome
Joints showing improvement of FOI semiquantitative
score at month 3 were more likely to improve clinically
by month 6 than joints that stayed consistent or deterio-
rated with their FOI semiquantitative score (32–37%
versus 18–20%). Logistic regression analysis, however,
failed to produce reliable models. No positive correlation
could be found between improvement of semiquantita-
tive FOI score after 3 months and joint status after
6 months. Also no association between improvement in
FOI scores of more than 30% at month 12 and JADAS
minimal disease activity or JADAS remission could be
shown.
Comparison of FOI, US and CE
The total number of joints evaluated for the hand region
was 2970. Figure 3 summarizes CE, FOI and US results
on the single joint level, showing the differences between
the joints concerning frequency of detection of path-
ology by examination technique. FOI detected the high-
est number of joints (947 joints, 32%). Abnormal US
findings were present in 527 of 2550 joints (20.7%) eval-
uated by US. A total 519 of the evaluated joints (17.5%)
had active arthritis CE. A high number of joints (627
joints, 66.2%) showing increased signal intensity by FOI
were rated clinically inactive by CE. Of the joints rated
active in CE, 61.7% also showed FOI increased signal in-
tensity. A total of 199 joints with clinical abnormalities
did not show signaling by FOI (Table 2).
Also 513 (61.7%) joints that did not show sonographic
signs of synovial thickening, effusions or hyperperfusion
were detected by FOI. Especially, phase 2 showed increased
signal intensity more often than the other phases and com-
posite image.
On US examination, 211 of the 519 (40.6%) clinically
active joints over all three time points showed effusion,
164 (31.6%) synovial thickening and 47 (9%) signs of
hyperperfusion.
Ultrasonography did not detect signs of effusion, signs
of synovial thickening or signs of hyperperfusion in nu-
merous joints that were clinically classified as active.
Effusions and synovial thickening were detected by US
in 219 (8.9%) and 211 (8.6%) of 2451 clinically inactive
joints and hyperperfusion was detected by power Dop-
pler in 73 (3.0%) clinically inactive joints (Table 2).
Agreement of FOI with US was analyzed with obvious
differences between different joints and in the different
phases of FOI. Interestingly, agreement was 75–100%
in DIP joints and MCP 1 (phase 2, CI), was 64–92%
(CI) and 72–91% (phase 2) for MCP 2–5 and was 41–
63% (CI) and 38–69% (phase 2) for PIP 2–4. A high
variance between patients was also detected: mean
agreement over patients (for all joints) ranged from 33
to 100% with a width of the confidence interval from
16 to 21%, depending on the compared pair of analysis
methods.
(See figure on previous page.)
Fig. 2 a FOI of a patient treated with adalimumab. Row A, baseline; row B, week 12; row C, week 24; column 1, phase 1; column 2, phase 2;
column 3, phase 3; column 4, composite image. At baseline, signals detected were grade 3 over PIP 3 of the right hand in phases 1 and 2 and
composite image. Left-hand PIP 2–5 showed grade 2 signals in phase 2 and grade 1 signal in phase 3 and composite image. Left-hand PIP 1
showed grade 2 in phase 2, grade 0 in phase 3 and grade 1 in composite image. After 12 weeks of treatment, improvement of signal intensity
was visible. Especially, right-hand PIP 3 still shows grade 3 signal in phase 2. Further reduction of signaling was noted at week 24. b FOI of a
patient with polyarticular JIA who started etanercept treatment. Row A, baseline; row B, week 12; row C, week 24; row D, week 52; column 1, phase
1; column 2, phase 2; column 3, phase 3; column 4, composite image. At baseline, both wrists, both side PIP 2–5 and DIP 2–4 showed grade 3
signals in phase 2 but grade 1 in phase 3. Both DIP 5 showed weaker signals. Twenty-four-week imaging, especially in phase 2, demonstrates
subclinical activity. At clinical examination the patient already had no active joints. Upon constant clinical remission on treatment, there is further
improvement of FOI findings visible after 1 year
Fig. 3 Clinical, US and FOI results on the single joint level (all points
of time summarized). Clinical examination considered active joint
definition. US considered any sign of effusion, synovial thickening
or PD positivity. FOI considered signal enhancement in any phase.
ex examination, FOI fluorescence optical imaging, PIP proximal
interphalangeal joint, MCP metacarpophalangeal joint,
US ultrasonography
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FOI in phase 2 agreed best with detection of US effu-
sions and synovial thickening, while the detection of
PDUS hyperperfusion correlated best with FOI in phase
1 and to a slightly lesser extent phase 2.
Specificity of FOI compared with CE and US as the
standard of reference showed high percentages for all
parameters. Comparison of FOI phase 2 with clinical
and US parameters showed specificity between 73 and
80%, composite image 82–87% and the other phases
around or over 90%. Comparison of US parameters of
inflammation and CE as standard of reference specificity
was between 86 and 97% (Table 3).
Sensitivities comparing FOI and US with CE as the
standard of reference as well as comparing FOI with US
as the standard of reference were lower, with FOI phase
2 delivering the best values (45–56%) (Table 4).
ROC curves comparing FOI and US versus CE as
the standard of care showed the highest values of
the AUC for FOI phase 2 (AUC = 0.67 (95% CI
0.64–0.70)) and US B-mode joint effusions (AUC =
0.68 (95% CI 0.65–0.71)), followed by FOI composite
image (AUC 0.63 (95% CI 0.60–0.66)) and US B-
mode synovitis (AUC = 0.63 (95% CI 0.60–0.66))
(Fig. 4). Comparing FOI with US B-mode parameter
joint effusions, phase 2 (AUC = 0.68 (95% CI 0.65–
0.71)) followed by composite image (AUC = 0.63
(95% CI 0.60–0.66)) had the highest AUC values.
Comparing FOI with US B-mode parameter syno-
vitis, FOI phase 2 (AUC = 0.64 (95% CI 0.61–0.67))
and FOI phase 1 (AUC = 0.63 (95% CI 0.59–0.66))
had the highest AUC values. When calculating AUC
with PDUS as the reference, FOI phase 1 had the
highest values (AUC = 0.72 (95% CI 0.67–0.78))
(Figs. 5 a–c).
Safety
During the 24 weeks of this study, 15 adverse events
(AE) were reported in 10 different patients. These in-
cluded six infectious events, four events with gastro-
intestinal complaints, three patients with flare of JIA and
two intraarticular injections. None of the events were
serious. No events in correlation to FOI examination
were noted.
Discussion
Musculoskeletal ultrasonography (in GSUS and PDUS)
provides an imaging method which has a solid compo-
nent in the clarification of inflammatory joint diseases.
A disadvantage of the method is the relatively strong in-
vestigator dependency [18].
Table 2 Number of joints from a total of 2970 evaluated joints at three different points of time and comparison of number of joints






























































Data on US examination were available for 2550 joints in total
FOI fluorescence optical imaging, PD Power Doppler mode, US ultrasonography
aPercentages refer to columns/rows
Table 3 Sensitivities: comparison of FOI parameters and parameters of clinical examination and US parameters, and comparison of
US parameters and clinical examination parameters
Reference FOI US
Composite image Phase 1 Phase 2 Phase 3 Joint effusion Synovitis Hyperperfusion
power Doppler
Clinical active joints 0.395 0.314 0.543 0.160 0.471 0.360 0.103
Clinical swollen joints 0.394 0.323 0.534 0.169 0.474 0.365 0.103
Clinical tender joints 0.315 0.237 0.442 0.108 0.306 0.269 0.068
LOM 0.481 0.423 0.664 0.209 0.497 0.440 0.173
US joint effusion 0.393 0.316 0.565 0.191
US synovitis 0.358 0.358 0.522 0.139
Hyperperfusion by power Doppler 0.306 0.604 0.477 0.126
FOI fluorescence optical imaging, LOM limitation of motion, US ultrasonography
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Morphological features of the inflammation are hyper-
vascularization, increased blood perfusion and capillary
permeability [19]. The (neo)angiogenesis is a very early
event in the pathogenesis of chronic inflammation [20].
The angiogenesis of the synovial membrane leads to a
dense capillary network in the inflamed joint membrane.
Vasodilatation and increased capillary permeability
maintain synovitis.
It has been shown in rheumatoid arthritis patients that
the synovial vascularization correlates with the disease
activity of an affected joint [21]. Arthrosonographic pro-
cedures, including power Doppler sonography, are lim-
ited in resolution, however, and are not capable of
displaying an increased blood flow in the submillimeter
region and thus on the capillary plane.
Magnetic resonance imaging (MRI) is today regarded
as the gold standard for the representation of synovitis.
Furthermore, bone marrow edema detectable in MRI is
the strongest independent predictor of the radiological
progression of rheumatoid arthritis [22, 23]. The exact sig-
nificance of MRI for the diagnosis and prognosis of an
early arthritis has not yet been clarified conclusively [24].
Overall, MRI is used for early diagnosis in clinical routine
and above all in clinical trials. For standardization, the
OMERACT criteria for the use and evaluation of MRI
were developed [25]. However, there are limitations to the
use of MRI in everyday practice due to the high cost of an
examination and the limited availability. The use of gado-
linium and some contraindications also limit their use in
clinical routine. Furthermore, there were several limita-
tions especially in younger children, such as maintaining
an immobile position or the necessity for sedation.
In human medicine, FOI methods have so far been
used predominantly in ophthalmology as fluorescence
angiography for the imaging diagnostics of retinal and
choroidal diseases. Furthermore, FOI use is described in
vascular surgery, in neurosurgery after clipping of a
brain aneurysm in oncology to delineate tumor tissue
and in plastic and reconstructive surgery [9, 26, 27].
FOI is a relatively new imaging technique for the de-
tection of inflammation and arthritis in the joints of the
hand by visualizing altered microcirculation and angio-
genesis in adults with rheumatoid arthritis [9, 28]. FOI
findings agreed well with US [10, 11] and MRI [11] find-
ings in two studies with 252 and 32 RA patients and 46
and 6 patients respectively without signs of inflamma-
tory disease as control groups. Early arthritis as well as
subclinical inflammation could be detected by FOI.
There are almost no data concerning FOI use in
pediatric patients with JIA. Werner et al. [29] described
FOI use and results in three children. The aim of this
study was to evaluate patients with JIA of hand and
Table 4 Specificities: comparison of FOI parameters and parameters of clinical examination and US parameters, and comparison of
US parameters and clinical examination parameters
Reference FOI US
Composite image Phase 1 Phase 2 Phase 3 Joint effusion Synovitis Hyperperfusion
power Doppler
Clinical active joints 0.865 0.902 0.791 0.958 0.897 0.906 0.969
Clinical swollen joints 0.856 0.896 0.777 0.955 0.887 0.899 0.967
Clinical tender joints 0.848 0.884 0.767 0.947 0.862 0.888 0.962
LOM 0.859 0.903 0.785 0.957 0.874 0.899 0.974
US joint effusion 0.856 0.909 0.784 0.959
US synovitis 0.841 0.904 0.762 0.945
Hyperperfusion by power Doppler 0.818 0.888 0.730 0.935
FOI fluorescence optical imaging, LOM limitation of motion, US ultrasonography
Fig. 4 ROC curves for FOI parameters in phases 1–3 and CI and US
parameter B-mode joint effusion, B-mode synovitis and PDUS
compared with clinical examination (active joint). Area under the
curve (95% CI): FOI phase 1, 0.61 (0.58–0.64); FOI phase 2, 0.67
(0.64–0.70); FOI phase 3, 0.56 (0.53–0.59); FOI CI, 0.63 (0.60–0.66); US
joint effusion, 0.68 (0.65–0.71); US synovitis, 0.63 (0.60–0.66); PDUS,
0.53 (0.50–0.56). ROC Receiver operating characteristic
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finger joints using the FOI technique along with US and
CE, and to show its usefulness for demonstration of im-
provement upon treatment. Thus a follow-up analysis
before and after 12 and 24 weeks of treatment (either
methotrexate or a biologic antirheumatic drug) using the
FOI technique in comparison with US and CE was per-
formed in an open-label study. Clinical findings were all
as expected. A high rate of treatment success on either a
newly initiated therapy with methotrexate or a biologic
was documented, similar to that observed in other trials,
with earlier improvement in the biologics cohort.
As one result of our study, the number of joints with in-
creased signal intensity in FOI was higher than the number
of joints rated clinically active and even higher than the
joints with signs of inflammation on US. These findings are
consistent with the results of former studies using FOI in
adults [10, 11]. In comparative studies of CE and GSUS,
PDUS, and MRI, inflammatory changes were documented
in clinically asymptomatic joints [30–32]. It can be assumed
that FOI detected clinical and also subclinical activity.
There were differences in the specific phases of the ana-
lysis. The interpretation of the different phases is still not
clear. Especially, phase 2 showed increased signal intensity
in more joints than any other phase, including the com-
posite image. Comparison of FOI with CE showed that
phase 2 was best at detecting clinical active joints and also
showed more activity in clinical inactive joints compared
with the other FOI phases. FOI phase 2 also agreed best
with US signs of synovial thickening and effusions. This
may be the most sensitive phase and may be best suited to
detect subclinical activity.
Phase 3 rarely showed increased FOI signals. In the
former studies in adults, the authors considered phase 3
to show increased capillary permeability in which ICG is
more persistent than normal [10, 11].
In joints with hyperperfusion detected by PDUS, FOI
phase 1 most often showed increased signal intensity,
followed by phase 2. This can also be shown in the ROC
curves; when comparing the different FOI phases with
PDUS, FOI phase 1 reached the best AUC values. As pro-
posed by studies in adult patients, phase 1 may mirror in-
creased vascularity as a sign of high disease activity [10, 11].
With CE as the standard of reference, FOI and US
showed moderate sensitivities and high specificities,
partly due to the high number of negative results. The
findings for sensitivity and specificity for FOI with US as
the standard of reference were comparable. This could
also be shown in the ROC curves. Compared with CE,
FOI phase 2 and US B-mode joint effusions were the
most accurate parameters with similar values for the
AUC. FOI phase 2 also had the highest AUC values
when compared with the US mode parameters of joint
effusion and synovitis. Because of the lack of an assured
standard of reference, the interpretation of sensitivity
and specificity is a delicate issue. Of course the majority
of examined joints were expected to be inactive. Specifi-
city was influenced by higher rates of positive findings in
FOI compared with the other two methods. Because of
the lack of a control group and an assured standard of
reference like histopathological findings, sensitivity and
specificity should be valued carefully. Results for agree-
ment were added to complete the diagnostic description,
but it should be considered that high numbers are partly
based on the high amount of negative results.
In the detection of inflammatory changes, FOI was
more sensitive than CE. The higher rate of positive find-
ings compared with GDUS/PDUS suggests that the
method is more sensitive than the other two procedures.
It could be argued that only mild increases in FOI signal
intensity might not be a sign of active arthritis and
Fig. 5 ROC curves for FOI parameters in phases 1–3 and CI compared with US parameters B-mode joint effusion, B-mode synovitis and PD
hyperperfusion. a US parameter B-mode joint effusion (area under the curve (95% CI)): FOI phase 1, 0.61 (0.58–0.64); FOI phase 2, 0.68 (0.65–0.71);
FOI phase 3, 0.57 (0.54–0.61); FOI CI, 0.63 (0.60–0.66). b US parameter B-mode synovitis (area under the curve (95% CI)): FOI phase 1, 0.63 (0.59–
0.66); FOI phase 2, 0.64 (0.61–0.67); FOI phase 3, 0.54 (0.51–0.57); FOI CI, 0.59 (0.56–0.63). c US parameter PD hyperperfusion (area under the curve (95%
CI)): FOI phase 1, 0.72 (0.67–0.78); FOI phase 2, 0.61 (0.56–0.66); FOI phase 3, 0.53 (0.47–0.58); FOI CI, 0.55 (0.50-0.61). ROC Receiver operating characteristic
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discreet findings in FOI should be interpreted carefully.
Only FOI signals attributable to and limited to a specific
joint were rated as FOI-positive joints. Also, Werner et
al. [10, 11] state in their former studies that, because
healthy subjects and controls with arthralgia but without
signs of inflammatory disease had virtually no patho-
logical increased signal intensity in FOI using the Xira-
lite method, the detected FOI signals appear to reflect
actual inflammatory activity and are not all to be inter-
preted as false-positive findings.
Using MRI as a standard reference method, ICG-
assisted fluorescence-optical diagnostics demonstrated
high sensitivity (up to 85%) and high specificity (up to
95%) for the detection of MRI synovitis and tenosyno-
vitis, as well as high consistency rates with MRI [10].
Unfortunately we were not able to also include MRI ana-
lyses in our study.
Improvement after 12 and 24 weeks of antirheumatic
treatment could be shown with all three techniques, while
the decrease in the number of joints with a FOI signal was
slower than the clinical changes. To a lesser extent this
was seen for the US as well. This indicates that joints be-
coming clinically inactive with treatment may show un-
detected subclinical activity, even after months of
treatment. This is obvious in our patient shown in Fig. 3b
who had residual inflammation at week 24 demonstrated
by FOI although being in clinical remission. Hence, FOI
can be useful to assess treatment response.
FOI improvement at month 3 did not show reliable pre-
dictive value for clinical improvement at month 6. Al-
though more joints had changed from active at month 0
to inactive at month 6, when they had improved in FOI
semiquantitative scores at month 3 (all FOI phases) the
difference from 19 to about 35% is not huge. Logistic re-
gression analysis could not produce reliable models either.
One problem might be differences in sample size, because
the vast majority of joints were inactive in the first place
and did not show clinical or FOI changes during the in-
vestigation. But calculating only with initially active joints
did not change the probability of outcome prediction.
There were some limitations to our study. The mean
age of our patient cohort was relatively high, the youn-
gest patient being 9 years old. This was due to reduced
compliance in younger patients because the method-
ology is limited to older children able to comply with
the procedure which takes 6 minutes and to the arm
length of the children.
One further limitation of the FOI method is the lack
of visualization of anatomical structures such as synovial
proliferation or erosion, as well as the limited ability to
assess the palmar inflammation, especially in the area of
the hand and MCP joints. Furthermore, any inflamma-
tion of the hand region, for example lacerations of the
skin, will result in increased signal intensity. In this
study all patient hands were also examined for signs of
inflammation and injury other than arthritis; this was
documented and visible findings were documented and
considered for FOI reading. Finally, FOI examination
was tolerated well, with no report of AE correlated with
the examination. We did not observe any serious adverse
events in our cohort and in no patients did the analysis
have to be stopped or interrupted.
Conclusion
ICG-supported FOI with the Xiralite method is a new
imaging method for rheumatological questions. This
technology allows sensitive detection of inflammatory
changes. It is a useful technique to supplement clinical
and ultrasonographic investigation in assessment of JIA
activity in the joints of the hand. It can provide useful
additional information for diagnosis and assessment of
treatment response in JIA. Subclinical activity probably
can be detected with this method. The procedure could
be particularly important for the diagnosis of early arth-
ritis as well as for follow-up under long-term anti-
inflammatory therapy or for evaluation of remission.
Abbreviations
AUC: Area under the curve; CE: Clinical examination; CHAQ: Childhood
Health Assessment Questionnaire; CI: Composite image; CRP: C-reactive
protein; DIP: Distal interphalangeal joint; DMARD: Disease-modifying
antirheumatic drug; ESR: Erythrocyte sedimentation rate; FOI: Fluorescence
optical imaging; GS: Grey-scale mode; ILAR: International League of
Rheumatology; ITT: Intention to treat; JADAS: Juvenile arthritis disease activity
score; JIA: Juvenile idiopathic arthritis; LOM: Limitation of motion;
MCP: Metacarpophalangeal joint; MRI: Magnetic resonance imaging;
MTX: Methotrexate; NRS: Numeric rating scale; OMERACT: Outcome Measures
in Rheumatology; PD: Power Doppler mode; PedACR: American College of
Rheumatology pediatric criteria; PIP: Proximal interphalangeal joint;




Unrestricted grant from Pfizer.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
AK analyzed the data and wrote the manuscript. GH conceived the study,
participated in its design and coordination, and was a major contributor to
the manuscript. GWJ contributed to the manuscript and provided statistical
analyses. IB analyzed the data and provided statistical support. DK, PTO, H-EL,
and KM performed examination and data collection at the respective centers.
SGW conceived the study, participated in its design and coordination, and read
the fluorescence optical images, and was a contributor to the manuscript. H-EL
conceived the study, and participated in its design and coordination. All authors
read and approved the final manuscript.
Competing interests
AK, GWJ, SGW, IB, H-EL, and DK declare no competing interests. PTO is on
the Advisory Board of Novartis. KM has received honoraria for lectures from
Pfizer, Roche and Pharm-Allergan. GH has received grants and honorary fees
from Abbvie, Pfizer, Novartis and Roche/Chugai.
Klein et al. Arthritis Research & Therapy  (2017) 19:147 Page 11 of 12
Consent for publication
By signing informed consent the participations in this study (patients and
parents) approved the use of their pseudonymized data for scientific analysis.
Ethics approval and consent to participate
The study was performed in compliance with the Declaration of Helsinki. The
study protocol was approved by the ethics committee Ärztekammer
Nordrhein (Number: 2012026) and ethics committee of the Charité university
clinic Berlin (Number EA2/039/12). Written informed consent forms were
obtained for all participants.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Centre for Paediatric Rheumatology, Department of Paediatrics, Asklepios
Clinic Sankt Augustin, Arnold-Janssen-Strasse 29, 53757 Sankt Augustin,
Germany. 2HELIOS Klinikum Duisburg, Klinik für Rheumatologie, Duisburg,
Germany. 3Department of Pediatric Oncology, Hematology and Clinical
Immunology, University Children’s Hospital, Medical Faculty,
Heinrich-Heine-University, Düsseldorf, Germany. 4Charité University Medicine
and Epidemiology Unit, German Rheumatism Research Centre, Berlin,
Germany. 5Institute of Medical Statistics, University of Cologne, Cologne,
Nordrhein-Westfalen, Germany. 6RHIO (Rheumatologie, Immunologie,
Osteologie) Düsseldorf, Düsseldorf, Germany. 7Department of Diagnostic and
Interventional Radiology, University Düsseldorf, Medical Faculty,
Moorenstraße 5, 40225 Düsseldorf, Germany.
Received: 22 February 2017 Accepted: 30 May 2017
References
1. Petty RE. Prognosis in children with rheumatic diseases: justification for
consideration of new therapies. Rheumatology (Oxford). 1999;38(8):739–42.
2. Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998;351(9107):
969–73.
3. Minden K, et al. Prognosis of patients with juvenile chronic arthritis and
juvenile spondyloarthropathy. J Rheumatol. 2000;27(9):2256–63.
4. Gompels LL, Lim NH, Vincent T, Paleolog EM. In vivo optical imaging in
arthritis—an enlightening future? Rheumatology (Oxford). 2010;49:1436–46.
5. Fischer T, Gemeinhardt I, Wagner S, et al. Assessment of unspecifi c near-
infrared dyes in laser-induced fluorescence imaging of experimental
arthritis. Acad Radiol. 2006;13:4–13.
6. Meier R, Krug C, Golovko D, et al. Indocyanine green-enhanced imaging of
antigen induced arthritis with an integrated optical imaging/radiography
system. ArthritisRheum. 2010;62:2322–7.
7. Ebert B, Berger J, Voigt J, et al. Early detection of rheumatoid arthritis in
humans by fluorescence imaging. Optical Society of America meeting.
Biomed. 2008; 2008 Mar 16-19; St. Petersburg, Florida. Biomedical Optics,
OSA Technical Digest, 2008. BTuF19.
8. Fischer T, Ebert B, Voigt J, et al. Detection of rheumatoid arthritis using non-
specific contrast enhanced fluorescence imaging. Acad Radiol. 2010;17:375–81.
9. Bremer C, Werner S, Langer HE. Assessing activity of rheumatic arthritis with
fluorescence optical imaging. Eur Musculoskelet Rev. 2009;4:96–100.
10. Werner SG, Langer HE, Ohrndorf S, Bahner M, Schott P, Schwenke C, et al.
Inflammation assessment in patients with arthritis using a novel in vivo
fluorescence optical imaging technology [published erratum appears in
Ann Rheum Dis 2012;71:1756 and Ann Rheum Dis 2013;72:156]. Ann Rheum
Dis. 2012;71:504–10.
11. Werner SG, Langer HE, Schott P, Bahner M, Schwenke C, Lind-Albrecht G, et
al. Indocyanine green-enhanced fluorescence optical imaging in patients
with early and very early arthritis. A comparative study with magnetic
resonance imaging. Arthritis Rheum. 2013;65:3036–44.
12. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al.
International League of Associations for Rheumatology. International
League of Associations for Rheumatology classification of juvenile idiopathic
arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.
13. Foeldvari I, Ruperto N, Dressler F, Häfner R, Küster RM, Michels H, et al. The
German version of the Childhood Health Assessment Questionaire (CHAQ) and
the Child Health Questionaire. Clin Exp Rheumatol. 2001;19(4 Suppl 23):71–4.
14. Consolaro A, et al. Development and validation of a composite disease activity
score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658–66.
15. Magni-Manzoni S, Epis O, Ravelli A, Klersy C, Veisconti C, Lanni S, Muratore
V, Sciré CA, Rossi S, Montecucco C. Comparison of clinical versus
ultrasound-determined synovitis in juvenile idiopathic arthritis. Arthritis
Rheum. 2009;61(11):1497–504.
16. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary
definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.
17. Consolaro A, et al. Remission, minimal disease activity, and acceptable
symptom state in juvenile idiopathic arthritis: defining criteria based on the
juvenile arthritis disease activity score. Arthritis Rheum. 2012;64(7):2366–74.
18. Lassere M, McQueen F, Østergaard M, et al. OMERACT Rheumatoid Arthritis
Magnetic Resonance Imaging Studies. Exercise 3: an international multicenter
reliability study using the RA-MRI Score. J Rheumatol. 2003;30(6):1366–75.
19. Scheel AK, Schmidt WA, Hermann K-G, et al. Interobserver reliabiltiy of
rheumatologists performing musculoskeletal ultrasonography: results from a
EULAR "Train the trainers" course. Ann Rheum Dis. 2005;64(7):1043–9.
20. Andersson SE, Johansson A, Lexmuller K, Ekstrom GM. Physiological
characterization of mBSA antigen induced arthritis in the rat. II. Joint blood
flow, glucose metabolism, and cell proliferation. J Rheumatol. 1998;25:1778–84.
21. Kennedy A, Ng CT, Biniecka M, et al. Angiogenesis and blood vessel stability
in inflammatory arthritis. Arthritis Rheum. 2010;62:711–21.
22. McQueen FM, Benton N, Perry D, et al. Bone edema scored on magnetic
resonance imaging scans of the dominant carpus at presentation predicts
radiographic joint damage of the hands and feet six years later in patients
with rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1814–27.
23. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the
strongest predictor of subsequent radiographic progression in early
rheumatoid arthritis. Results from a 2-year randomised controlled trail
(CIMESTRA). Ann Rheum Dis. 2009;68(3):384–90.
24. Suter LG, Fraenkel L, Braithwaite RS. Role of magnetic resonance imaging in
the diagnosis and prognosis of rheumatoid arhtirits. Arthritis Care Res
(Hoboken). 2011;63(5):675–88.
25. Lindblad S, Hedfors E. Intraarticular variation in synovitis: local macroscopic
and microscopic signs of inflammatory activitiy are significantly correlated.
Arthritis Rheum. 1985;28(9):977–86.
26. Ishizawa T, Fukushima N, Shibahara J, et al. Real-time identification of liver cancers
by using indocyanin green fluorescent imaging. Cancer. 2009;115:2491–504.
27. Desmettre T, Devoisselle JM, Mordon S. Fluorescence properties and
metabolic features of indocyanine green (ICG) as related to angiography.
Surv Ophthalmol. 2000;45(1):15–27.
28. Fischer T, Ebert B, Voigt J, et al. Detection of rheumatoid arthritis using non-
specific contrast enhanced fluorescence imaging. Acad Radiol. 2010:17;375–81.
29. Werner SG, Langer HE, Horneff G. Fluorescence optical imaging of juvenile
arthritis. J Rheumatol. 2011;38(7):1447.
30. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An
explanation for the apparent dissociation between clinical remission and
continued structural deterioration in rheumatoid arthritis. Arthritis Rheum.
2008;58:2958–67.
31. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al.
Presence of significant synovitis in rheumatoid arthritis patients with
disease-modifying antirheumatic drug-induced clinical remission: evidence
from an imaging study may explain structural progression. Arthritis Rheum.
2006;54:3761–73.
32. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Wakefield R, et al. Should
imaging be a component of rheumatoid arthritis remission criteria? A
comparison between traditional and modified composite remission scores
and imaging assessments. Ann Rheum Dis. 2011;70:792–8.
Klein et al. Arthritis Research & Therapy  (2017) 19:147 Page 12 of 12
